^
    1year
    A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=10, Completed, Eucure (Beijing) Biopharma Co., Ltd | N=16 --> 10 | Trial completion date: Jul 2023 --> Mar 2023 | Trial primary completion date: Jul 2023 --> Mar 2023
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    YH003
    over1year
    Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours (ESMO 2023)
    Conclusions YH003 was well tolerated up to 3.0 mg/kg dose levels when combined with Toripalimab, and 0.3mg/kg was deemed the RP2D. YH003 has shown encouraging antitumour activity in patients with advanced solid tumours.
    Clinical • P1 data • Combination therapy • Metastases
    |
    CD40 (CD40 Molecule)
    |
    Loqtorzi (toripalimab-tpzi) • YH003
    2years
    A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=26, Completed, Eucure (Beijing) Biopharma Co., Ltd | Active, not recruiting --> Completed | N=60 --> 26 | Trial completion date: Dec 2022 --> May 2022
    Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    gemcitabine • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • YH003
    2years
    A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, Eucure (Beijing) Biopharma Co., Ltd | Trial completion date: Mar 2023 --> Dec 2022
    Trial completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    gemcitabine • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • YH003
    3years
    A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, Eucure (Beijing) Biopharma Co., Ltd | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    gemcitabine • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • YH003
    almost4years
    A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Eucure (Beijing) Biopharma Co., Ltd | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    gemcitabine • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • YH003